WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004100995) TARGETED DELIVERY OF ANTI-VIRAL COMPOUNDS THROUGH HEMOGLOBIN BIOCONJUGATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/100995    International Application No.:    PCT/CA2004/000741
Publication Date: 25.11.2004 International Filing Date: 17.05.2004
IPC:
A61K 47/48 (2006.01)
Applicants: HEMOSOL LP [CA/CA]; 2585 Meadowpine Blvd., Mississauga, Ontario L5N 8H9 (CA) (For All Designated States Except US).
ADAMSON, J., Gordon [CA/CA]; (CA) (For US Only).
BELL, David [CA/CA]; (CA) (For US Only).
NG, Nancy [CA/CA]; (CA) (For US Only).
BIESSELS, Peter [NL/CA]; (CA) (For US Only)
Inventors: ADAMSON, J., Gordon; (CA).
BELL, David; (CA).
NG, Nancy; (CA).
BIESSELS, Peter; (CA)
Agent: BERESKIN & PARR; 40 King Street West, Suite 4000, Toronto, Ontario M5H 3Y2 (CA)
Priority Data:
60/470,445 15.05.2003 US
60/513,575 24.10.2003 US
Title (EN) TARGETED DELIVERY OF ANTI-VIRAL COMPOUNDS THROUGH HEMOGLOBIN BIOCONJUGATION
(FR) ADMINISTRATION CIBLEE DE COMPOSES ANTIVIRAUX AU MOYEN DE BIOCONJUGUES A BASE D'HEMOGLOBINE
Abstract: front page image
(EN)This invention relates to targeted delivery of anti-viral compounds through protein bioconjugation. More particularly, it relates to an anti-viral compound conjugated to hemoglobin and to a method of treating a viral infection using said conjugate. The invention also provides a method of targeted drug delivery of an anti-viral nucleoside analogue to macrophages, cells comprising a hemoglobin receptor and to CD163 bearing cells.
(FR)L'invention concerne l'administration ciblée de composés antiviraux au moyen de bioconjugués protéiques. Elle concerne plus particulièrement un composé antiviral conjugué à de l'hémoglobine et une méthode de traitement d'une infection virale au moyen dudit conjugué. Elle concerne également une méthode d'administration ciblée d'un analogue de nucléoside antiviral à des macrophages, à des cellules comprenant un récepteur de l'hémoglobine et à des cellules comportant CD163.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)